SCHEMBL12552907

SCHEMBL12552907

CC1(C)OC[C@@H](COc2ccc(-c3c(C#N)c(N)nc(SCc4nc(-c5ccc(Cl)cc5)oc4-c4ccccc4)c3C#N)cc2)O1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 16/20 0.48
▸ SLC6A3 Q01959 1/20 0.48
▸ ADORA2B P29275 6/20 0.46
▸ ADORA2A P29274 2/20 0.45
▸ ADORA3 P0DMS8 1/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ RXFP1 Q9HBX9 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ PPARG P37231 1/20 0.44
▸ NCOA2 Q15596 1/20 0.44
▸ NCOA1 Q15788 1/20 0.44
▸ NCOA3 Q9Y6Q9 1/20 0.44
▸ MAPT P10636 1/20 0.43
▸ HTR1B P28222 1/20 0.43
▸ OPRK1 P41145 1/20 0.43
▸ FFAR4 Q5NUL3 1/20 0.43
▸ SIGMAR1 Q99720 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12552908 1.00 ADORA1 (0.48) ADORA1SLC6A3ADORA2BADORA2AADORA3
SCHEMBL12534896 0.93 ADORA1 (0.41) ADORA1SLC6A3ADORA2BADORA2AADORA3
SCHEMBL12534902 0.93 ADORA1 (0.41) ADORA1SLC6A3ADORA2BADORA2AADORA3
SCHEMBL12552840 0.91 ADORA1 (0.49) ADORA1SLC6A3ADORA2BADORA2AADORA3
SCHEMBL12552911 0.91 ADORA1 (0.49) ADORA1SLC6A3ADORA2BADORA2AADORA3
SCHEMBL12553059 0.90 ADORA1 (0.48) ADORA1SLC6A3ADORA2BADORA2AADORA3
SCHEMBL12553048 0.90 ADORA1 (0.48) ADORA1SLC6A3ADORA2BADORA2AADORA3
SCHEMBL12553062 0.90 ADORA1 (0.44) ADORA1ADORA2BADORA2AADORA3HTR1B
SCHEMBL12553096 0.90 ADORA1 (0.44) ADORA1ADORA2BADORA2AADORA3HTR1B
SCHEMBL12163650 0.89 RET (0.44) ADORA1SLC6A3ADORA2BADORA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9095582-B2 Substituted aryloxazoles and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-08-04 — — US disclosed
US-20140162981-A1 SUBSTITUTED ARYLOXAZOLES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-06-12 — — US disclosed
US-8440700-B2 Substituted aryloxazoles and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-05-14 — — US disclosed
US-20110130377-A1 SUBSTITUTED ARYLOXAZOLES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130377-A1 SUBSTITUTED ARYLOXAZOLES AND THEIR USE AADAC, CYP4X1, AGXT ADORA1 3589/4885SLC6A3 2005/4885ADORA2B 3694/4885
US-20140162981-A1 SUBSTITUTED ARYLOXAZOLES AND THEIR USE CYP4X1, AHR, AGXT ADORA1 2450/4885SLC6A3 2093/4885ADORA2B 3238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback